Pipeline

Our pipeline is focused on developing itolizumab as a potentially first-in-class treatment for multiple severe immuno-inflammatory disorders, including graft-versus-host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.

Transplant Science

EQUATE Phase 1b/2 trial actively enrolling

Positive interim data announced

  • Phase 1b/2
FDA Fast Track and
Orphan Drug Designation

Renal Disease

EQUALISE Phase 1b trial actively enrolling

  • Phase 1b
FDA Fast Track Designation

Pulmonary

EQUIP Phase 1b trial actively enrolling

  • Phase 1b

Biocon completed a Phase 1 study in healthy volunteers in Australia.